)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Terumo
Terumo (4543) investor relations material
Terumo 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic Growth and Business Overview
Achieved $7 billion in global sales across three segments: cardiac & vascular, medical care solutions, and blood & cell technologies, with 79% of revenue from overseas markets and operations in over 160 countries.
Diverse portfolio of more than 52,000 products and 29 production bases worldwide, supporting consistent revenue growth through organic expansion and strategic acquisitions.
Margin expansion to 20% targeted for FY2026, supported by disciplined operations, price adjustments, and divestment of non-core businesses.
FY2025 guidance targets 8% revenue growth and 24% operating profit growth, with OP margin reaching 17.8%, setting a strong foundation for FY2026.
Long-term vision centers on innovation, robust sales growth, and leadership through R&D, M&A, and evolving into a global top-tier medtech leader.
Core Business Drivers and Innovation
Vascular access products account for over 70% of cardiac & vascular segment revenue, with leadership in introducer sheaths, guidewires, and transforming commodity devices into high-value offerings.
Pioneered radial access technology, now the gold standard in PCI, and holds top global and domestic market shares in key products.
Launched innovative products like the Dual Sensor System and WEB Embolization System, targeting phased US entry and expanded clinical evidence, driving double-digit growth.
CDMO business leverages one-stop device development and manufacturing, aiming for $1 billion in sales in the 2030s, with 17% CAGR since FY17.
Blood and cell technologies segment driven by Rika plasma collection system, achieving rapid U.S. growth and maximizing recurring revenue.
M&A Strategy and OrganOx Acquisition
M&A guided by five criteria: technological excellence, competitive advantage, synergy, financial profile, and cultural fit.
OrganOx acquisition brings advanced perfusion technology, expanding from liver to kidney and potentially other organs, supporting innovation in organ transplantation.
OrganOx's NMP technology addresses organ supply bottlenecks, enabling use of more donor organs, supporting drug development, and improving transplant outcomes.
OrganOx expected to maintain high double-digit growth, with a revenue target of ¥100 billion within 10 years.
Post-merger integration emphasizes mutual communication, autonomy, and synergy creation.
CDMO: When will capacity expansion yield OP margin growth
OrganOx: Detail non-transplant growth opportunities
US market: How to differentiate in therapeutic areas
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Terumo earnings date
Q3 202613 Feb, 2026
Terumo
Next Terumo earnings date
Q3 202613 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Terumo Corporation develops, manufactures, and distributes medical devices and services. The company's products include airway management devices such as catheters, cannulas, balloons and valves; minimally invasive surgery systems; infusion systems; cartridges for dialysis machines; intrauterine systems for contraception; endoscopic systems for gastrointestinal endoscopy and bronchoscopy procedures; surgical lasers for eye surgery; films for X-rays or pictures of body organs; imaging apparatus for magnetic resonance images (MRIs) and computed tomography (CT) scans; home transfusion treatment machines; products used in blood conservation therapy such as apheresis machines used to separate blood components such as plasma or platelets from whole blood using centrifugal force. The company is based in Tokyo, Japan.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage